A
Alcista
Alcista · 25%URGN
$7.21
Precio del escenario
$34.560
-1.935 (-5.60%)Al cierre
Loading chart…
- Máximo
- 36.910
- Apertura
- 36.350
- Precio medio ponderado por volumen
- 35.24
- Volumen
- 1.06M
- Capitalización
- 697.98M
- Mínimo
- 34.260
- Importe
- 37.26M
- EV/EBITDA, TTM
- 554.53
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Análisis de IA of Urogen Pharma Ltd (URGN)
MantenerUrogen Pharma Ltd is currently not a strong buy due to its low RSI of 19.34, indicating it is oversold, but it has a significant upside potential with analyst price targets ranging from $50 to $75. The stock has experienced a recent decline of 11.04% over the past five days, which may present a buying opportunity if the price stabilizes. However, the risk remains with a forward P/E of 36.50, suggesting that the stock may be overvalued compared to its earnings potential.
Recomendaciones de analistas (4)
+16.46% de potencial alcista
Comprar
3 Comprar
1 Mantener
0 Vender
Actual: 34.56
Mínimo
31.00
Promedio
40.25
Máximo
55.00
Oppenheimer
Superar al mercado
$60
2026-08-06
Oppenheimer
2026-08-06
Precio objetivo
$60
Superar al mercado
H.C. Wainwright
Comprar
$75
2026-08-06
H.C. Wainwright
2026-08-06
Precio objetivo
$75
Comprar
Guggenheim
Comprar
$58
2026-08-06
Guggenheim
2026-08-06
Precio objetivo
$58
Comprar
TD Cowen
Comprar
$60
2026-08-05
TD Cowen
2026-08-05
Precio objetivo
$60
Comprar
Guggenheim
Comprar
$42
2026-07-21
Guggenheim
2026-07-21
Precio objetivo
$42
Comprar
Métricas de valoración
El PER previsto actual de Urogen Pharma Ltd (URGN) es 36.50, frente a su media de 5 años de -3.21.
Escenarios de precio de Alphio AI para URGN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con URGN en cartera
Cronología de eventos
Noticias
5.009-04NewsfilterUroGen Pharma Grants RSUs to 19 New Employees
8.508-20NASDAQ.COMUroGen Pharma Enters Investment and License Agreement with IntraGel
8.508-20PRnewswireIntraGel and UroGen Enter Strategic Investment Agreement
- 8.508-20Newsfilter
IntraGel Secures $7 Million Investment from UroGen for TumoCure Development
- 7.508-20Newsfilter
UroGen Partners with IntraGel for Oncology Product Development
Preguntas frecuentes sobre URGN, respondidas por Alphio AI
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Urogen Pharma Ltd is currently not a strong buy due to its low RSI of 19.34, indicating it is oversold, but it has a significant upside potential with analyst price targets ranging from $50 to $75. The stock has experienced a recent decline of 11.04% over the past five days, which may present a buying opportunity if the price stabilizes. However, the risk remains with a forward P/E of 36.50, suggesting that the stock may be overvalued compared to its earnings potential.
4 analysts cover URGN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 40.25.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.